TAVR and Anticoagulation: What Should We Do?

Transcatheter aortic valve replacement (TAVR) has consolidated as a valid strategy for certain groups of patients. However, approximately one third of those who require this therapy are being treated with anticoagulants (AC).

Anticoagulación y TAVI

Even though the current guidelines suggest interrupting anticoagulation to reduce bleeding risk, the available evidence has not yet fully elucidated this recommendation. 

This analysis of POPular PAUSE TAVI, included 858 patients treated with anticoagulants undergoing TAVR. 431 (50.2%) of these patients continued with AC (AC+), while the rest stopped AC and continued after procedure, according to treating physician criteria (AC-). 

The primary outcome was a composite of cardiovascular death, stroke, infarction, vascular complications or major bleeding within 30 days after procedure. 

Baseline group characteristics were similar: mean age 81, one third women, 3.8 STS Score, atrial fibrillation in 96% of cases, 4.5 CHA2DS2-VASc Score, 78% were hypertensive, 30% diabetic, 33% had a history of CABG, 15% had infarction history, 11% stroke, 10% TIA, 13% COPD, there was kidney function deterioration in 50% and prior TAVR in 7%.

Read also: RODIN-CUT: Successive Cutting Balloon Technique in Calcified Lesions.

There were no differences in primary end point, with 16.5% incidence in AC+ patients vs 14.8% in AC- (risk difference: 1.7 percentual points, CI 95%: −3.1 to 6.6; P = 0.18 for non-inferiority). Neither were there differences in cardiovascular mortality, all cause stroke, infarction, major bleeding or major vascular complications. 

Conclusion

In TAVR patients, periprocedural anticoagulation was shown non-inferior vs. AC interruption as regards the incidence of the combined end point of cardiovascular death, stroke, infarction, major vascular complications and major bleeding at 30 days. 

Original Title: Continuation versus Interruption of Oral Anticoagulation during TAVI. POPular PAUSE TAVI Trial.

Reference: D.J. van Ginkel, et al. N Engl J Med 2025;392:438-49. DOI: 10.1056/NEJMoa2407794.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....

TAVR in Pure Native Aortic Regurgitation: Are Dedicated Devices Truly Superior?

This systematic meta-analysis assessed the efficacy and safety of transcatheter aortic valve replacement (TAVR) in patients with pure native aortic regurgitation. The emergence of...

Dual Antiplatelet Therapy in Diabetic Patients with AMI: De-Escalation Strategy

Diabetes Mellitus (DM) is a common comorbidity in patients hospitalized for acute coronary syndrome (ACS) of increasing prevalence over the last decade, associated with...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....